Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
0301 basic medicine
03 medical and health sciences
Virology
Science
Immunology
Q
Structural biology
Article
3. Good health
DOI:
10.1016/j.isci.2022.104914
Publication Date:
2022-08-11T15:53:11Z
AUTHORS (23)
ABSTRACT
The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and prevent viral neutralization. Here, we used a directed evolution-based approach to engineer three neutralizing antibodies for enhanced binding to S protein. The engineered antibodies showed increased in vitro functional activity in terms of neutralization potency and/or breadth of neutralization against viral variants. Deep mutational scanning revealed that higher binding affinity reduces the total number of viral escape mutations. Studies in the Syrian hamster model showed two examples where the affinity-matured antibody provided superior protection compared to the parental antibody. These data suggest that monoclonal antibodies for antiviral indications would benefit from affinity maturation to reduce viral escape pathways and appropriate affinity maturation in vaccine immunization could help resist viral variation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (60)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....